Logo image of ZLNA.OL

ZELLUNA ASA (ZLNA.OL) Stock Fundamental Analysis

OSL:ZLNA - Euronext Oslo - NO0013524942 - Common Stock - Currency: NOK

14.5  -0.8 (-5.23%)

Fundamental Rating

2

Overall ZLNA gets a fundamental rating of 2 out of 10. We evaluated ZLNA against 71 industry peers in the Biotechnology industry. ZLNA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. ZLNA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

In the past year ZLNA has reported negative net income.
ZLNA had a negative operating cash flow in the past year.
ZLNA had negative earnings in each of the past 5 years.
In the past 5 years ZLNA always reported negative operating cash flow.
ZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFZLNA.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M -200M

1.2 Ratios

The Return On Assets of ZLNA (-173.53%) is worse than 81.69% of its industry peers.
With a Return On Equity value of -243.21%, ZLNA is not doing good in the industry: 63.38% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -173.53%
ROE -243.21%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ZLNA.OL Yearly ROA, ROE, ROICZLNA.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

ZLNA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ZLNA.OL Yearly Profit, Operating, Gross MarginsZLNA.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200 -250

4

2. Health

2.1 Basic Checks

ZLNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ZLNA.OL Yearly Shares OutstandingZLNA.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ZLNA.OL Yearly Total Debt VS Total AssetsZLNA.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -11.03, we must say that ZLNA is in the distress zone and has some risk of bankruptcy.
ZLNA has a worse Altman-Z score (-11.03) than 77.46% of its industry peers.
ZLNA has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
ZLNA's Debt to Equity ratio of 0.00 is amongst the best of the industry. ZLNA outperforms 92.96% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -11.03
ROIC/WACCN/A
WACCN/A
ZLNA.OL Yearly LT Debt VS Equity VS FCFZLNA.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 3.62 indicates that ZLNA has no problem at all paying its short term obligations.
ZLNA has a Current ratio of 3.62. This is in the better half of the industry: ZLNA outperforms 70.42% of its industry peers.
ZLNA has a Quick Ratio of 3.62. This indicates that ZLNA is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 3.62, ZLNA is in the better half of the industry, outperforming 73.24% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.62
Quick Ratio 3.62
ZLNA.OL Yearly Current Assets VS Current LiabilitesZLNA.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M 500M

1

3. Growth

3.1 Past

ZLNA shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -5.77%.
EPS 1Y (TTM)-5.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90.69%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 35.22% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y87.94%
EPS Next 2Y35.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ZLNA.OL Yearly Revenue VS EstimatesZLNA.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2M 4M 6M 8M
ZLNA.OL Yearly EPS VS EstimatesZLNA.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -20 -40 -60

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ZLNA. In the last year negative earnings were reported.
Also next year ZLNA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ZLNA.OL Price Earnings VS Forward Price EarningsZLNA.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ZLNA.OL Per share dataZLNA.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6 -8

4.3 Compensation for Growth

A more expensive valuation may be justified as ZLNA's earnings are expected to grow with 35.22% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y35.22%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

ZLNA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ZELLUNA ASA

OSL:ZLNA (5/5/2025, 7:00:00 PM)

14.5

-0.8 (-5.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-13 2025-02-13/amc
Earnings (Next)05-08 2025-05-08
Inst Owners18.55%
Inst Owner ChangeN/A
Ins Owners6.3%
Ins Owner ChangeN/A
Market Cap293.33M
Analysts42.22
Price Target58.65 (304.48%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-266.55%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.55
P/tB 3.55
EV/EBITDA N/A
EPS(TTM)-5.81
EYN/A
EPS(NY)-5.25
Fwd EYN/A
FCF(TTM)-8.08
FCFYN/A
OCF(TTM)-8.08
OCFYN/A
SpS0
BVpS4.09
TBVpS4.09
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -173.53%
ROE -243.21%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0.61%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.62
Quick Ratio 3.62
Altman-Z -11.03
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)2.96%
Cap/Depr(5y)41.24%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-5.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-90.69%
EPS Next Y87.94%
EPS Next 2Y35.22%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y29.89%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year41.46%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y13.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.92%
OCF growth 3YN/A
OCF growth 5YN/A